Amphotericin B Molecular Organization as an Essential Factor to Improve Activity/Toxicity Ratio in the Treatment of Visceral Leishmaniasis

Author： Sánchez-Brunete J.A.   Dea M.A.   Rama S.   Bolás F.   Alunda J.M.   Torrado-Santiago S.   Torrado J.J.  

Publisher： Informa Healthcare

ISSN： 1061-186X

Source： Journal of Drug Targeting, Vol.12, Iss.7, 2004-08, pp. : 453-460

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amphotericin B Lipid Complex: In Visceral Leishmaniasis

By Goldsmith David R.   Perry Caroline M.  

Drugs, Vol. 64, Iss. 17, 2004-01 ,pp. : 1905-1911

Adis International

Access to resources Recommend Favorite

Liposomal Amphotericin B: Therapeutic Use in the Management of Fungal Infections and Visceral Leishmaniasis

By Coukell A.J.   Brogden R.N.  

Drugs, Vol. 55, Iss. 4, 1998-04 ,pp. : 585-612

Adis International

Access to resources Recommend Favorite

Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

By Gupta Swati   Dube Anuradha   Vyas Suresh P.  

Journal of Drug Targeting, Vol. 15, Iss. 6, 2007-07 ,pp. : 437-444

Informa Healthcare

Access to resources Recommend Favorite

New Formulations and Derivatives of Amphotericin B for Treatment of Leishmaniasis

By  

Mini Reviews in Medicinal Chemistry, Vol. 6, Iss. 2, 2006-02 ,pp. : 153-162

Bentham Science Publishers

Access to resources Recommend Favorite

Liposomal amphotericin B as a treatment for human leishmaniasis

By Balasegaram Manica  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 493-510

Informa Healthcare

Access to resources Recommend Favorite